Dr. Marc Hansen
Dr. Hansen is a faculty member in the Department of Physiology and Developmental Biology at Brigham Young University. His work is focused on epithelial-mesenchymal transitions (EMT) and how this relates to cancer progression and cancer metastasis. Dr Hansen has published over 15 articles in epithelial cell biology using a wide range of technical approaches and is also the inventor on several international patents for inhibitors of EMT. Dr Hansen received his B.S. from Brigham Young University in 1997 and his PhD from the Cancer Biology program Stanford University in 2002. He founded Frost Biologic in 2007 based on a proprietary phenotypic screening technology that gave rise to several of Frost's current pipeline programs.
Dr. Adam Siddiqui-Jain
Dr. Siddiqui-Jain brings more than ten years of profesional experience in the discovery and development of anticancer drugs. He previously held the position of Associate Director of Experimental Biology and Screening at Cylene Pharmaceuticals, where he was the lead project scientist on several oncology drug discovery programs. Two of these programs successfully yielded clinical candidates, Quarfloxin (phase 1) and the first-in-class protein Kinase CK2 inhibitor CX-4945 (phase 1). Prior to his arrival at Cylene Pharmaceuticals, Dr. Siddiqui-Jain worked in Laurence Hurley’s Lab at the University of Arizona, where he discovered the active conformation of the G-quadruplex DNA regulatory structure in the c-Myc promoter and is the first-named author on the subsequent PNAS paper (2002) that has since been referenced more than 650 times. Dr. Siddiqui-Jain holds a Ph.D. in Biological Chemistry and has published more than 40 publications and patents.
Dr. Stewart Chipman
Dr. Chipman is a biotech executive with over 20 years of experience in building and leading scientific teams focused on the discovery and development of novel human therapeutics in the fields of inflammation, metabolic bone diseases, and oncology. Currently Dr. Chipman is Chief Scientific Officer & President of Aequus BioPharma, Inc., where he co-founded the company and is a co-inventor of Aequus’ GlycoPolymer technology platform. He was previously Vice President of Research at Cell Therapeutics Inc. where he lead a multi-national team developing multiple novel oncology drug candidates, Director of Biomolecular Screening at Immunex where his team provided expertise in assay development, high-throughput screening robotics and synthetic chemistry to enable several small molecule lead discovery and optimization programs, and Director of Biology at ArQule in Boston. Prior to pursuing his career in biotechnology Dr. Chipman was an Associate Professor of Medicine at The Johns Hopkins University School of Medicine. Dr. Chipman received his B.S. in Biology at Boston University and Ph.D. in Biochemistry from the Boston University School of Medicine. He has co-authored more than 40 peer-reviewed scientific papers and is a co-inventor on eight U.S. and foreign patents.